Limet R, Lepage G, Grondin C M
Ann Thorac Surg. 1977 Jun;23(6):529-33. doi: 10.1016/s0003-4975(10)63696-x.
A comparison of the incidence of thromboembolic (TE) episodes was made in three groups of patient who underwent aortic valve replacement with the cloth-covered Starr-Edwards prostheses. Group 1 consisted of patients who received anticoagulants for either the entire period of follow-up or for a period of variable duration, after which these agents were no longer administered. When anticoagulants were stopped, 22 patients were categorized as Group 3 for study. Group 2 comprised patients who never received anticoagulants. Of the 147 patients followed in Group 1, 14 suffered one episode of TE. Six patients experienced major emboli; 3 of them died. Twenty of the 82 patients followed in Group 2 (no anticoagulants) suffered TE complications. There were 10 episodes of major emboli. Five of the 22 patients in Group 3 suffered an episode (all major) of TE. It is concluded from this study that anticoagulants should be given permanently to all patients with cloth-covered Starr-Edwards prostheses. Indeed, there is no period after operation when the incidence of TE is so low that anticoagulation may be safely discontinued.
对三组接受带布覆盖的斯塔尔-爱德华兹人工心脏瓣膜进行主动脉瓣置换术的患者的血栓栓塞(TE)发作发生率进行了比较。第1组由在整个随访期间或在一段可变持续时间内接受抗凝剂治疗,之后不再使用这些药物的患者组成。当停用抗凝剂时,22名患者被归类为第3组进行研究。第2组包括从未接受过抗凝剂治疗的患者。在第1组随访的147名患者中,14名发生了1次TE发作。6名患者发生了严重栓塞;其中3人死亡。在第2组(未使用抗凝剂)随访的82名患者中,20名出现了TE并发症。有10次严重栓塞发作。第3组的22名患者中有5名发生了1次(均为严重)TE发作。这项研究得出的结论是,对于所有使用带布覆盖的斯塔尔-爱德华兹人工心脏瓣膜的患者,都应永久性给予抗凝剂。事实上,术后没有任何时间段TE的发生率会低到可以安全停用抗凝治疗。